[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nail-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nail-psoriasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,73,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634926","clinical-study-on-the-medical-device-proxera-psomed-30-for-the-treatment-of-nail-psoriasis-evaluation-of-safety-and-efficacy-100634926",false,"NCT07546032","Clinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy","Evaluation of the Safety and Efficacy of the Medical Device PROXERA PSOMED 30 in the Treatment of Nail Psoriasis: a Sponsored, Interventional, Single-center, Randomized, Single-site, Intrapatient Controlled Study (NAPSI)","NAPSI","Inclusion Criteria:\n\n* Diagnosis of Psoriasis\n* Diagnosis of nail psoriasis for at least 6 months (NAPSI ≥ 3)\n* Male or female\n* Age between 18 and 65 years\n* Willingness to participate in the study and signing the informed consent form\n\nExclusion Criteria:\n\n* Known hypersensitivity or intolerance to any component of the product.\n* Concomitant therapy with systemic immunomodulatory drugs (e.g., cyclosporine, apremilast), except methotrexate (MTX), the use of which will be compatible with the study.\n* Concomitant therapy with biologic agents such as anti-TNFα, anti-IL17, or anti-IL23.\n* Concomitant topical therapy with topical steroids (TCS), topical calcineurin inhibitors (TCI), vitamin D analogues, and combinations.\n* Pregnant or breastfeeding women","ALL","18 Years","65 Years",{"count":21,"type":22},21,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this interventional clinical study is to evaluate the safety and efficacy of PROXERA PSOMED 30, a topical medical device containing 30% urea, for the treatment of nail psoriasis in adults with nail psoriasis. The primary question the study aims to answer is whether PROXERA PSOMED 30 improves the clinical signs of nail psoriasis more effectively than a control treatment (Vaseline).\n\nResearchers will compare two similar target nails in the same participant, one treated with PROXERA PSOMED 30 and the other with Vaseline, to determine whether the active treatment leads to greater improvement in Nail Psoriasis Severity Index (NAPSI) scores over 24 weeks. The study will also evaluate local tolerability, patient satisfaction, and digital photographs of the treated nails.\n\nParticipants will be men or women between the ages of 18 and 65 with nail psoriasis for at least 6 months and a target NAPSI nail score of 3 or higher. A total of 21 participants is expected.\n\nParticipants will:\n\napply PROXERA PSOMED 30 to one target nail and petroleum jelly to the opposite target nail twice daily for 24 weeks; attend follow-up visits at baseline and after 4, 12, and 24 weeks; undergo nail assessments using the NAPSI score; have digital photographs of treated nails; report tolerability, satisfaction, and any adverse events during the study.",[28],"Nail Psoriasis",[28,30,31,32,33,34,35,36,37],"Psoriasis","PROXERA PSOMED 30","Urea","Topical Medical Device","Intra-patient Controlled Study","Single-Blind Study","Nail Psoriasis Severity Index","Petrolatum","NOT_YET_RECRUITING","2026-04-15",{"date":41,"type":42},"2026-04-22","ACTUAL",{"date":44,"type":22},"2026-04-28",{"date":46,"type":22},"2026-12-08",{"name":48,"class":49},"ICIM International S.r.l.","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100617011","phase-2-topical-use-of-2-tofacitinib-for-nail-psoriasis-an-exploratory-clinical-study-100617011","NCT07313072","Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study","Inclusion Criteria: Age ≥ 18 years;\n\n* Presence of nail psoriasis in at least one fingernail or toenail;\n* Patients not using systemic medication, or without adequate response to systemic medication after at least 6 months of use;\n* Ability to read, understand, and sign the Informed Consent Form (ICF) and the Consent Form for Images, Presentations, and Scientific Publications.\n\nExclusion Criteria: Pregnant or breastfeeding women or those planning to become pregnant during the study period;\n\n* History of sensitivity to any components of the study product;\n* Initiation of systemic medication for nail psoriasis less than six months prior.",{"count":58,"type":22},10,[60],"PHASE2","To evaluate the efficacy and safety of topical 2% tofacitinib nail lacquer in nail psoriasis, using the NAPSI and DLQI scales before and after 26 weeks of treatment.",[28],"2026-03-16",{"date":65,"type":42},"2026-03-18",{"date":67,"type":22},"2026-03",{"date":69,"type":22},"2027-03",{"name":71,"class":72},"Hexsel Dermatology Clinic","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100595212","phase-3-study-to-assess-efficacy-safety-and-tolerability-of-a-nail-patch-in-patients-with-nail-fragility-mychosis-psoriasis-100595212","NCT07029516","Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis","A Randomized, Double Blind, Placebo-controlled, Unicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of a Multi-funtion Toe Nail Patch in Patients Affected by Nail Fragility, Nail Mychosis and Psoriasis","Inclusion Criteria:\n\n* aged 18 years or older Fragility Nails Distal Subungual Onychomycosis Nail Psoriasis affecting ≤75% of the nail bed according to a photographic documentation and to a subjective evaluation by the Investigator.\n\nExclusion Criteria:\n\n* Patients that have proximal subungual onychomycosis, if their distal subungual onychomycosis is extended into the proximal portion of the nail or if it affects \\>75% of the nail.\n* Patients with conditions known to cause abnormal nail appearance, immunosuppression and signs of severe peripheral circulatory insufficiency\n* Patients who had used topical antifungal, anti-psoriasis nail treatment within one month or systemic antifungal treatment within three months.\n* Patients who have participated in another clinical nail study during the previous three months\n* Patients who have a known allergy to any of the study treatments.\n* Patients with unrelated nail disorders: onychomycosis, nail psoriasis, genetically induced onychodystrophy.\n* Patients with other nail disorders, active or severe psoriasis elsewhere, other autoimmune or inflammatory diseases.",{"count":81,"type":22},72,[83],"PHASE3","A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis 72 patients in 6 subgroups Treatment duration 3 months + 1 month follow-up",[28,86,87],"Nail Damage","Mycosis",[89,90,91,92],"ONICOMYCOSIS","PATCH","UREA","PSORIASIS","RECRUITING","2026-01-22",{"date":96,"type":42},"2026-01-26",{"date":98,"type":22},"2026-02",{"date":100,"type":22},"2026-12",{"name":102,"class":49},"Wooshin Labottach Co., Ltd.",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":50},"100577788","real-world-study-of-xeligekimab-for-moderate-to-severe-plaque-psoriasisxp-real-100577788","NCT06802848","Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study","Inclusion Criteria:\n\nPatients who meet all the following criteria will be included in this study:\n\n1. Patients 18 years of age or older;\n2. Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening;\n3. Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time;\n4. Patients who are willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria will be excluded from this study:\n\n1. Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium);\n2. Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution;\n3. Patients with other contraindications specified in the prescribing information;\n4. Patients concurrently participating in other clinical studies;\n5. Patients under other conditions or circumstances that investigators do not consider appropriate to include.",{"count":111,"type":22},1000,"OBSERVATIONAL","Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.",[115,116,117,28,118,119],"Plaque Psoriasis","Psoriatic Arthritis","Scalp Psoriasis","Palmoplantar Psoriasis","Genital Psoriasis",[115,116,117,28,118,119,121,122,123,124,125],"Comorbidities of Psoriasis","Xeligekimab","IL-17A","GR1501","Antibodies, Monoclonal","2025-01-26",{"date":128,"type":42},"2025-01-31",{"date":130,"type":22},"2025-01-30",{"date":132,"type":22},"2026-12-31",{"name":134,"class":49},"Chongqing Genrix Biopharmaceutical Co., Ltd"]